We are live on ! Find out more
BMY.RT

Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT

Delisted

BMY.RT was delisted on the 31st of December, 2020.

Back to rankings

4 hedge funds and large institutions have $0 invested in Bristol-Myers Squibb Company Contingent Value Rights in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 8 → 4 (-4)

100% less capital invested

Capital invested by funds: $6.4M → $0 (-$6.4M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
4
Holders Change
-4
Holders Change %
-50%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
JCI
Jet Capital Investors
New York
-$3.46M
2
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$2.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
JCI
1
Jet Capital Investors
New York
– -$3.46M -2,661,301 Closed
Tudor Investment Corp
2
Tudor Investment Corp
Connecticut
– -$2.94M -2,264,818 Closed

BMY.RT Hedge Fund Activity: Q3 2021 in Review

4 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q3 2021, worth a combined $0 — down 100% from $6.4M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BMY.RT and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Jet Capital Investors, exiting entirely with an estimated $3.46M sold.

  • 4 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q3 2021, down from 8 in Q2 2021.
  • Funds reported $0 of Bristol-Myers Squibb Company Contingent Value Rights stock for Q3 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q3 2021 and 4 closed out, a net change of -4 holders.
  • The largest Bristol-Myers Squibb Company Contingent Value Rights seller in Q3 2021 was Jet Capital Investors, an estimated $3.46M sold.

Based on aggregated 13F filings for Q3 2021.